Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34+ stem cell-derived natural killer cells
- Development stage
- Unknown
- Lead developer
- Agency for Medical Research and Development
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD34+ stem cell-derived natural killer cells is an autologous adoptive cell therapy being developed by Hiroshima University and the Japan Agency for Medical Research and Development (AMED). The therapeutic process involves mobilizing a patient's peripheral blood CD34+ hematopoietic stem cells using granulocyte colony-stimulating factor (G-CSF), followed by apheresis and ex vivo differentiation into mature natural killer (NK) cells. These cells are then re-infused intravenously into the patient. The therapy is primarily indicated for the prevention of recurrence in patients with high-risk hepatocellular carcinoma (HCC) who have undergone curative hepatectomy. The mechanism of action relies on the innate ability of NK cells to recognize and eliminate residual malignant cells through direct cytotoxicity, potentially overcoming the immunosuppressive tumor microenvironment.
- Other names
- Autologous CD34+ stem cell-derived NK cellsCD34-NK cellsCD-34-NK cellsCD 34-NK cells
02
Targets
NKG2DL (NKG2D ligand family)TNFRSF10B (DR5)TNFR (TNF receptor family)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)MHC I (MHC class I})
Beyond the preview
Go deeper on CD34+ stem cell-derived natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34+ stem cell-derived natural killer cells.